[
    {
        "utterance": "Shwetadwip Chowdhury: anyone you can either log in and write it yourself or you can tell me what to write in. I took a few notes while we were talking, but I don't think that I have nearly a comprehensive list. ",
        "annotations": {
            "encourage participation": "The speaker is inviting others to contribute to the notes or provide information to be included.",
            "acknowledge contribution": "The speaker acknowledges that they took notes but recognizes that their list may not be comprehensive, thus acknowledging the need for others' input."
        }
    },
    {
        "utterance": "Brian Pogue: Is there sort of a higher or super structure to what we discussed? ",
        "annotations": {
            "ask clarifying question": "Brian is asking for a higher-level organization or summary of the discussion, seeking clarification on the overall structure."
        }
    },
    {
        "utterance": "Ping Wang: Excuse me, can you add my name? I mean, I'm sorry. ",
        "annotations": [
            {
                "ask clarifying question": "Ping Wang is asking Shwetadwip Chowdhury to add their name to the notes being taken, which is a request for clarification or addition to the record."
            }
        ]
    },
    {
        "utterance": "Brian Pogue: Yeah, I think. ",
        "annotations": {
            "express agreement": "Brian agrees with a prior statement or idea, indicated by his utterance 'Yeah, I think.'"
        }
    },
    {
        "utterance": "Ping Wang: I don't have access to the slide. I don't know. I couldn't find it from the Google Doc. ",
        "annotations": {
            "express frustration": "Ping expresses frustration about not being able to access the slide, indicating a problem hindering their participation.",
            "ask clarifying question": "Ping's statement implies a question about how to access the slide, as they couldn't find it in the Google Doc."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Uh, why don't I just put this in the chat and maybe you can um. ",
        "annotations": {
            "propose decision": "Shwetadwip is suggesting a course of action to share the information by putting it in the chat."
        }
    },
    {
        "utterance": "Ping Wang: Okay. Oh, somebody already did it. Somebody already did it. There you go. ",
        "annotations": [
            {
                "acknowledge contribution": "Ping Wang acknowledges that someone else has already added her name to the slide, as she requested earlier."
            }
        ]
    },
    {
        "utterance": "Brad Smith: Well, I think the first point here might be that this problem gets a lot harder as you get further up the chain, you know, so so obviously it on mono layers or cultures or even as we've learned from Crystal embryos, but then once you start getting to an immune system, you're in trouble. ",
        "annotations": {
            "present new idea": "Brad introduces the idea that the problem becomes more complex as you move up the biological chain, from mono layers to systems with an immune system, which is a new consideration in the discussion.",
            "expand on existing idea": "Brad expands on the complexity of the problem by providing examples of increasing difficulty, starting from mono layers and cultures to systems with an immune system."
        }
    },
    {
        "utterance": "Brad Smith: And that's something maybe I hadn't appreciated. There's definitely threshold points where this problem gets a lot harder a lot quickly. ",
        "annotations": {
            "expand on existing idea": "Brad is expanding on his previous point about the problem getting harder as you go up the chain, adding that he hadn't fully appreciated this and that there are threshold points where the problem escalates quickly.",
            "provide supporting evidence": "Brad provides his realization about the problem getting harder as evidence to support his point about the challenges in the chain."
        }
    },
    {
        "utterance": "Crystal Rogers: I would say the issue here is yeah, scale, time, and then complexity. ",
        "annotations": {
            "present new idea": "Crystal introduces the concepts of 'scale', 'time', and 'complexity' as key issues, which are new to the discussion."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Uh, time meaning acquisition time or what? ",
        "annotations": {
            "ask clarifying question": "Shwetadwip asks for clarification on what Crystal meant by 'time', indicating he needs more information to understand the previous statement."
        }
    },
    {
        "utterance": "Crystal Rogers: Well, that that's relevant too, but no, I actually meant um well, yeah, I guess that's relevant acquisition time, but also the amount of time that it takes between when you give the epitope or the treatment or the marker and the time that you're then going to image it whether or not that gets diluted or lost or attacked. So there's two different time issues. ",
        "annotations": {
            "explain or define term or concept": "Crystal is clarifying what she meant by 'time' in the context of the problem, specifying that it refers to both acquisition time and the time between treatment and imaging, which builds upon the previous discussion about the challenges of the problem.",
            "expand on existing idea": "Crystal is elaborating on the previously mentioned issue of 'time' by providing more details about what aspects of time are relevant to the problem, adding to the discussion about scale and complexity."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Uh, what's up? ",
        "annotations": {
            "ask clarifying question": "Shwetadwip is asking for clarification or for someone to explain what is happening or being discussed, as indicated by the phrase 'what's up?'."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Uh, to dimensional imaging. ",
        "annotations": {
            "explain or define term or concept": "Shwetadwip is likely explaining or defining what he means by \"to dimensional imaging\" in the context of the discussion about scale, time, and complexity of imaging."
        }
    },
    {
        "utterance": "Allison Dennis: You're definitely going to have to economize on words though here. ",
        "annotations": {
            "offer constructive criticism": "Allison suggests to economize on words, which is a critique intended to improve the clarity or conciseness of the discussion or a document being created."
        }
    },
    {
        "utterance": "Brian Pogue: Right. ",
        "annotations": {
            "express agreement": "Brian Pogue says 'Right', which indicates that he agrees with the previous statement made by Allison Dennis about economizing on words."
        }
    },
    {
        "utterance": "Brian Pogue: Or I could. ",
        "annotations": {
            "assign task": "Given the context of needing to economize on words, Brian is offering to take on the task of editing or summarizing the text."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Just decrease it. ",
        "annotations": {
            "propose decision": "Shwetadwip is suggesting a concrete action to take, which is to decrease something, likely referring to the length of the text as Allison mentioned the need to economize on words."
        }
    },
    {
        "utterance": "Brian Pogue: There you go. ",
        "annotations": {
            "express agreement": "Brian Pogue is agreeing with Shwetadwip Chowdhury's suggestion to decrease something, likely the amount of text on a slide."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Um. ",
        "annotations": {
            "None": "This utterance does not contain any content that can be categorized by the codebook."
        }
    },
    {
        "utterance": "Arnold Hayer: With increasing with increasing complexity also the uh the ability or the opportunity to measure subcellular properties will decrease, I guess. ",
        "annotations": {
            "present new idea": "Arnold introduces a new idea that as complexity increases, the ability to measure subcellular properties decreases, which has not been previously mentioned."
        }
    },
    {
        "utterance": "Arnold Hayer: In a simple transparent system you might be able to monitor like a few different parameters, but uh in a very complex system you might just be able to track the movement of cells and that's all. ",
        "annotations": {
            "expand on existing idea": "Arnold is expanding on the previously discussed idea of complexity by explaining how the ability to measure subcellular properties decreases with increasing complexity."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Um, yeah, sorry, can you repeat that? ",
        "annotations": {
            "ask clarifying question": "Shwetadwip asks Arnold to repeat his statement, indicating a need for clarification on what Arnold said about complexity and measuring subcellular properties."
        }
    },
    {
        "utterance": "Arnold Hayer: No, I just meant uh because you said it task gets harder as you start moving to more complex cell systems, also if you you know, you might find a sweet spot where you can make really interesting discoveries by by being able and um to to track the cells and in addition to the just tracking their movement, you might be able to monitor intracellular activities at the same time or some other properties. ",
        "annotations": {
            "expand on existing idea": "Arnold expands on Brad's point that the task gets harder with more complex cell systems by suggesting that there might be a sweet spot where interesting discoveries can be made by tracking cells and monitoring intracellular activities.",
            "provide supporting evidence": "Arnold supports his idea by mentioning that in a complex system, one might be able to track the movement of cells and monitor intracellular activities, which could lead to interesting discoveries."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: So how do we find that sweet spot? ",
        "annotations": {
            "ask clarifying question": "Shwetadwip asks how to find the 'sweet spot' that Arnold mentioned, seeking clarification on how to achieve the balance between complexity and measurable properties in cell systems."
        }
    },
    {
        "utterance": "Arnold Hayer: Pushing I don't know. That's the question, right? ",
        "annotations": {
            "express frustration": "Arnold expresses frustration about not knowing how to find the 'sweet spot' for making interesting discoveries in complex cell systems, after Shwetadwip asked how to find it."
        }
    },
    {
        "utterance": "Arnold Hayer: Well, I think finding the ideal find finding a transparent uh model and uh finding good reporters and uh and uh a good a gentle a gentle way of of imaging the system. ",
        "annotations": {
            "expand on existing idea": "Arnold is expanding on the previous discussion about the challenges of imaging complex systems and how to find a 'sweet spot' for making discoveries, by suggesting specific approaches to finding this sweet spot.",
            "propose decision": "Arnold is suggesting concrete choices for the group, such as finding a transparent model, good reporters, and a gentle way of imaging the system."
        }
    },
    {
        "utterance": "Brian Pogue: Um, I think Arnold was heading down the route of um. ",
        "annotations": {
            "acknowledge contribution": "Brian acknowledges Arnold's contribution, but does not agree or expand on it."
        }
    },
    {
        "utterance": "Mark Selimyer: Finding good three uh good three dimensional system because we're pretty good at two dimensional right now, but like finding a good three dimensional system to look at cell movements is maybe a good interim step before getting to to animals. ",
        "annotations": {
            "expand on existing idea": "Mark is building on the previous discussion about the challenges of imaging in complex systems and suggesting a specific approach to address those challenges, which is to find a good three-dimensional system.",
            "propose decision": "Mark is suggesting a concrete step for the group to consider: finding a good three-dimensional system as an interim step before moving to animal models."
        }
    },
    {
        "utterance": "Ping Wang: We talk talk a lot about the single cell imaging. Um, probably we should add that. Yeah, I mean. ",
        "annotations": {
            "propose decision": "Ping Wang suggests adding single cell imaging to the discussion, indicating a proposed action for the group to take."
        }
    },
    {
        "utterance": "Mark Selimyer: Ping doesn't think it's a good idea. ",
        "annotations": {
            "reject idea": "Mark is stating that Ping does not think single cell imaging is a good idea, which means Ping is rejecting the idea of adding it."
        }
    },
    {
        "utterance": "Mark Selimyer: Ha ha ha. ",
        "annotations": {
            "express humor": "The utterance \"Ha ha ha\" indicates that Mark Selimyer is expressing humor, likely in response to the preceding exchange about single cell imaging."
        }
    },
    {
        "utterance": "Ping Wang: No, no, no. I I think it's a brilliant idea. I like the like a push the push the technology. I mean, uh hard I mean to to help help the people like me for the application. I just I just want to have like a more justification. What are you going to do for the single cell imaging? I really like this. ",
        "annotations": [
            {
                "express agreement": "Ping Wang expresses agreement with the idea of single cell imaging, clarifying that he likes the idea.",
                "ask clarifying question": "Ping Wang asks for more justification on what they are going to do for single cell imaging, seeking more details about the approach."
            }
        ]
    },
    {
        "utterance": "Mark Selimyer: No, I I I tend to agree with you. So I was throwing you under the bus there. But you know, it's generally populations of cells that we care most about, especially like therapeutically or you know, I I actually actually let me take it back. Let me take it back. So it could be that single cell is super important for something like development, you know, developmental biology, sort of what Crystal studies. ",
        "annotations": {
            "express agreement": "Mark explicitly agrees with Ping's idea about single cell imaging, after initially joking about disagreeing.",
            "expand on existing idea": "Mark expands on the discussion about single cell imaging by suggesting that while populations of cells are often the focus, single cell imaging could be important for developmental biology, connecting it to Crystal's work.",
            "correct previous statement": "Mark initially stated that populations of cells are what they care about, but then he takes it back and says that single cell is super important for something like development."
        }
    },
    {
        "utterance": "Mark Selimyer: But then maybe on like the therapeutic side it's more like, well, you put in 50 million car T cells and you just want to know where they go and you need to have some. ",
        "annotations": {
            "expand on existing idea": "Mark is expanding on the previous discussion about single-cell imaging and its relevance, now focusing on the therapeutic side and the importance of tracking cell populations, building on the discussion of single cell imaging and its applications."
        }
    },
    {
        "utterance": "Ping Wang: I can come up one application I can come up with I'm not sure if that's that's feasible. Like for the detecting the what does the static cells. You can generate something like um pad reporter genes and detect the single cells uh detached from the primary lesion and that's a good application for the for the like early detection. That's very critical for the cancer. ",
        "annotations": {
            "present new idea": "Ping Wang introduces a new application for single-cell imaging involving the detection of metastatic cells using reporter genes, which hasn't been discussed before.",
            "provide supporting evidence": "Ping Wang explains that detecting metastatic cells is critical for early cancer detection, providing a justification for the application of single-cell imaging.",
            "expand on existing idea": "Ping Wang builds on the idea of single cell imaging by suggesting a specific application involving the use of reporter genes to detect metastatic cells."
        }
    },
    {
        "utterance": "Mark Selimyer: So would it be safe to say that single cell is. ",
        "annotations": {
            "ask clarifying question": "Mark is asking a question to clarify the role or importance of single-cell imaging, given the prior discussion about its potential applications and limitations."
        }
    },
    {
        "utterance": "Mark Selimyer: Helpful to determine, you know, underlying biology and that population movements may be more important for understanding therapies. ",
        "annotations": {
            "expand on existing idea": "This utterance builds upon the previous discussion about single-cell imaging versus population movements, adding details about their respective importance in understanding underlying biology and therapies.",
            "provide supporting evidence": "The statement provides a logical reasoning to strengthen the idea that single cell is helpful to determine underlying biology and that population movements may be more important for understanding therapies."
        }
    },
    {
        "utterance": "Mark Selimyer: Maybe. ",
        "annotations": {
            "express agreement": "Mark Selimyer is agreeing with his previous statement about single cell analysis being helpful to determine underlying biology and population movements being more important for understanding therapies."
        }
    },
    {
        "utterance": "Ping Wang: Yeah. ",
        "annotations": {
            "express agreement": "Ping Wang agrees with Mark Selimyer's statement about single cell imaging and population movements being important for understanding therapies."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: All right. ",
        "annotations": {
            "acknowledge contribution": "The utterance 'All right' acknowledges the preceding discussion and contributions from other team members."
        }
    },
    {
        "utterance": "Crystal Rogers- UC Davis: mechanism in vivo. ",
        "annotations": {
            "expand on existing idea": "Crystal is adding to the discussion about complexity and imaging, and this utterance likely refers to expanding on the idea of studying mechanisms within a living organism, building upon the previous discussion of single-cell imaging and its applications."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Um yeah, we also talked about I liked the conversation about iron oxide particles. I personally don't um have any experience with that, but I thought that was a really nice contrast agent as well as the micro bubbles for ultrasound. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges the conversation about iron oxide particles, indicating recognition of a previously discussed topic.",
            "express agreement": "The speaker expresses agreement by stating they liked the conversation about iron oxide particles and thought they were a nice contrast agent."
        }
    },
    {
        "utterance": "Brad Smith: Well that seemed to be part of the the two paradigms here. One was that you would have to label exogenous cells and then you introduce them and then you track them and so then the question becomes what's the best label and you've just talked of a couple and then the that that paradigm changes to one where you're now presumably adding a contrast agent that's going to go and find a certain cell population and then stick to it or maybe longitudinally lay, you know, keep redosing all the time. There seem to be two general strategies. Each have their own particular technical challenges. ",
        "annotations": {
            "explain or define term or concept": "Brad explains the two paradigms: labeling exogenous cells for tracking and using contrast agents to target specific cell populations, clarifying the different strategies being discussed.",
            "expand on existing idea": "Brad expands on the discussion about contrast agents and microbubbles by describing two general strategies for cell tracking and their respective technical challenges, building upon the previous mention of these agents by Shwetadwip."
        }
    },
    {
        "utterance": "Brian Pogue: And yeah, Mark, you you were talking about biologically altering cells so that you could image them. And I presume that is ex vivo and then introduced in vivo. You know. ",
        "annotations": {
            "expand on existing idea": "Brian is expanding on Mark's previously mentioned idea of biologically altering cells for imaging, adding the detail that this process likely occurs ex vivo before reintroduction in vivo.",
            "explain or define term or concept": "Brian is explaining the concept of biologically altering cells for imaging, clarifying that it involves an ex vivo process followed by in vivo introduction."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Um okay, is this uh ",
        "annotations": [
            {
                "ask clarifying question": "Shwetadwip is about to ask a question to clarify something that was previously discussed, as indicated by the utterance being cut off mid-sentence."
            }
        ]
    },
    {
        "utterance": "Ping Wang: I I have one um one point I'm not sure. I mean, if we should add I I think probably theranostics as I said um label the cells using the reporter gene to say the cells. That's one one um one thing um um I mean, probably we should also uh pay some attention on the uh theranostic like protect the cells or control the cells function after you put the cells in for the transplantation. Um I don't know. I have idea um because of this uh COVID-19 uh vaccine, uh we had we had work on the SRI uh SRA um conjugation to the nanoparticles to uh silence the harmful genes for the cells related to apoptosis or related to the new rejection. Um I was fascinated uh to read the papers and I I also I got the vaccine uh to to know uh the the nanoparticle can deliver the RNA to to your immune cells. So um I mean if we can um work on some like imaging to see the um how this RNA uh works because because um because um before this uh COVID-19 before this uh vaccine uh it's hard for me to understand how you can deliver um like RNA to the cells and the cells going to translate to the protein and this protein can can be recognized by um immune cells. ",
        "annotations": [
            {
                "present new idea": "Ping Wang introduces the idea of theranostics, specifically labeling cells with reporter genes to track them, and protecting/controlling cell function post-transplantation, which hasn't been explicitly discussed before."
            },
            {
                "provide supporting evidence": "Ping Wang provides the example of COVID-19 vaccines and siRNA conjugation to nanoparticles as evidence for the feasibility of delivering RNA to cells to silence harmful genes, drawing from their own experience and fascination with the technology."
            }
        ]
    },
    {
        "utterance": "Shwetadwip Chowdhury: Where should I put that, Ping? ",
        "annotations": {
            "assign task": "Shwetadwip is asking Ping where to incorporate Ping's suggestion about theranostics, essentially assigning Ping the task of indicating where the information should be placed."
        }
    },
    {
        "utterance": "Ping Wang: I would suggest ",
        "annotations": [
            {
                "propose decision": "Ping Wang is about to suggest a concrete choice or action for the group, as indicated by the phrase \"I would suggest\"."
            }
        ]
    },
    {
        "utterance": "Shwetadwip Chowdhury: So we're like fighting for space here, so what would be the best place to put it? ",
        "annotations": {
            "ask clarifying question": "Shwetadwip is asking where to put Ping's suggestion about theranostics, given the limited space on the slide."
        }
    },
    {
        "utterance": "Ping Wang: I would suggest have like another one like theranostics imaging. ",
        "annotations": {
            "propose decision": "Ping suggests adding another category for theranostics imaging, building on the previous discussion about single-cell imaging, contrast agents, and biologically altering cells."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Okay. ",
        "annotations": {
            "acknowledge contribution": "The utterance 'Okay' acknowledges Ping's suggestion to add 'theranostics imaging' without necessarily agreeing or expanding on it."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Theranostics. ",
        "annotations": {
            "expand on existing idea": "Ping Wang suggested adding theranostics as a point, and Shwetadwip Chowdhury is now writing it down, expanding on Ping's suggestion."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Um ",
        "annotations": {
            "None": "This utterance does not contain any content that can be coded."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: How do you spell that? I don't I I haven't heard that word before. ",
        "annotations": {
            "ask clarifying question": "Shwetadwip asks how to spell \"theranostics\", indicating a need for clarification on the term that Ping introduced in the previous utterances."
        }
    },
    {
        "utterance": "Ping Wang: Therapy. Therapy plus diagnose and then ",
        "annotations": {
            "explain or define term or concept": "Ping Wang is explaining the components of the word \"theranostics\" for Shwetadwip, who has never heard the word before."
        }
    },
    {
        "utterance": "Ping Wang: Theranostics. ",
        "annotations": {
            "explain or define term or concept": "Ping Wang is defining the term \"theranostics\" for Shwetadwip, who has not heard the word before."
        }
    },
    {
        "utterance": "Brad Smith: Yeah. ",
        "annotations": {
            "express agreement": "Brad Smith says \"Yeah\", which confirms his agreement with a prior statement."
        }
    },
    {
        "utterance": "Ping Wang: I can uh I know I have ",
        "annotations": {
            "None": "This utterance is incomplete and does not express a complete idea or action, so no code applies."
        }
    },
    {
        "utterance": "Brad Smith: Okay. ",
        "annotations": {
            "express agreement": "Brad Smith says \"Okay\", which indicates agreement with the previous discussion about theranostics imaging."
        }
    },
    {
        "utterance": "Brad Smith: Yeah. ",
        "annotations": {
            "express agreement": "Brad Smith says \"Yeah,\" which expresses agreement with the previous statement by Ping Wang about theranostics imaging."
        }
    },
    {
        "utterance": "Brad Smith: Okay. ",
        "annotations": {
            "express agreement": "Brad Smith says 'Okay', which indicates agreement with the immediately preceding statement by Ping Wang about theranostics."
        }
    },
    {
        "utterance": "Brad Smith: Okay. ",
        "annotations": {
            "express agreement": "Brad Smith says \"Okay\", which expresses agreement with the previous discussion about theranostics imaging."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Okay. ",
        "annotations": {
            "acknowledge contribution": "Shwetadwip Chowdhury says \"Okay\" after Ping Wang explains theranostics imaging, acknowledging Ping's contribution."
        }
    },
    {
        "utterance": "Brad Smith: Okay. ",
        "annotations": {
            "express agreement": "Brad Smith says \"Okay\", which indicates agreement with the previous discussion about theranostics imaging."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Okay. ",
        "annotations": {
            "acknowledge contribution": "Shwetadwip Chowdhury says \"Okay\" after Ping Wang explains theranostics imaging, acknowledging Ping's contribution."
        }
    },
    {
        "utterance": "Brad Smith: Okay. ",
        "annotations": {
            "acknowledge contribution": "Brad Smith says 'Okay' after Ping Wang explains theranostics imaging, acknowledging Ping's contribution."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Okay. ",
        "annotations": {
            "acknowledge contribution": "Shwetadwip Chowdhury says \"Okay\" after Ping Wang explains theranostics imaging, acknowledging Ping's contribution."
        }
    },
    {
        "utterance": "Brad Smith: Okay. ",
        "annotations": {
            "express agreement": "Brad Smith says \"Okay\", which indicates agreement with the previous statement."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Okay. ",
        "annotations": {
            "acknowledge contribution": "The utterance \"Okay\" acknowledges Ping's contribution of the idea of theranostics imaging, without necessarily agreeing or expanding on it."
        }
    },
    {
        "utterance": "Brad Smith: Okay. ",
        "annotations": {
            "express agreement": "Brad Smith says 'Okay' which expresses agreement with the previous discussion about theranostics imaging."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Okay. ",
        "annotations": {
            "acknowledge contribution": "Shwetadwip Chowdhury says \"Okay\" after Ping Wang explains theranostics imaging, acknowledging Ping's contribution."
        }
    },
    {
        "utterance": "Brad Smith: Okay. ",
        "annotations": {
            "express agreement": "Brad Smith says \"Okay\", which indicates agreement with the previous statement or suggestion."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Okay. ",
        "annotations": {
            "acknowledge contribution": "The utterance 'Okay' acknowledges Ping Wang's prior contribution of the idea of theranostics imaging."
        }
    },
    {
        "utterance": "Brad Smith: Okay. ",
        "annotations": {
            "express agreement": "Brad Smith says 'Okay' which indicates agreement with the previous statement by Shwetadwip Chowdhury."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Okay. ",
        "annotations": {
            "express agreement": "The utterance 'Okay' expresses agreement with the previous statement or suggestion, indicating understanding and acceptance."
        }
    },
    {
        "utterance": "Brad Smith: Okay. ",
        "annotations": {
            "express agreement": "Brad Smith says \"Okay\", which indicates agreement with the previous statement."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Okay. ",
        "annotations": {
            "acknowledge contribution": "The utterance \"Okay\" acknowledges Ping Wang's previous contribution of suggesting 'theranostics imaging' as a point to add."
        }
    },
    {
        "utterance": "Brad Smith: Okay. ",
        "annotations": {
            "express agreement": "Brad Smith says \"Okay\", which indicates agreement with the previous statement or suggestion."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Okay. ",
        "annotations": {
            "acknowledge contribution": "The utterance 'Okay' acknowledges Ping Wang's previous contribution of suggesting 'theranostics imaging' as a point to add."
        }
    },
    {
        "utterance": "Brad Smith: Okay. ",
        "annotations": {
            "express agreement": "Brad Smith says \"Okay\", which indicates agreement with the previous statement or suggestion."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Okay. ",
        "annotations": {
            "acknowledge contribution": "Shwetadwip Chowdhury says \"Okay\" after Ping Wang explains theranostics imaging, acknowledging Ping's contribution."
        }
    },
    {
        "utterance": "Brad Smith: Okay. ",
        "annotations": {
            "express agreement": "Brad Smith says \"Okay\", which indicates agreement with a prior statement or suggestion."
        }
    },
    {
        "utterance": "Shwetadwip Chowdhury: Okay. ",
        "annotations": {
            "acknowledge contribution": "The utterance 'Okay' acknowledges the previous speaker's contribution, indicating understanding or agreement without further elaboration."
        }
    },
    {
        "utterance": "Brad Smith: Okay. ",
        "annotations": {
            "express agreement": "Brad Smith says \"Okay\", which indicates agreement with the previous statement."
        }
    },
    {
        "utterance": "Mark Selimyer (UPenn): Not too much. There's, yeah, there are things like FDG that measures your metabolism, but you're looking at the body's own metabolism, um, and up regulated in immune cells. So there's a group down at Johns Hopkins, um, Sanjay Jane's group has been working on this and they've got some, um, labeled sorbitol for pet imaging, which is kind of cool because we don't take, we don't use sorbitol as a carbon source, but bugs do. Um, we're using an antibiotic, uh, trimethoprim to image bacteria themselves. Other people are using D amino acids. So there's a whole, you know, like chemistry world that's out there trying to develop probes specific for your question, um, you know, Brad about how to image pathology, um, using these probe development approaches. ",
        "annotations": [
            {
                "provide supporting evidence": "Mark provides examples of existing methods and research groups (FDG, Sanjay Jane's group) to support the idea of developing probes for imaging pathology, building on the previous discussion about imaging and labeling cells."
            },
            {
                "expand on existing idea": "Mark expands on the discussion of imaging and labeling cells by providing specific examples of probes and their applications, such as labeled sorbitol for PET imaging and trimethoprim to image bacteria."
            }
        ]
    },
    {
        "utterance": "Brian Pogue - Dartmouth: There's a lot of focus on immune probes, but it seems like metabolic probes are a whole lot easier because they wind up, the concentrations wind up being orders of magnitude higher. ",
        "annotations": {
            "present new idea": "The utterance introduces the idea of using metabolic probes as an alternative to immune probes, which is a new concept in the context of the discussion.",
            "provide supporting evidence": "The speaker supports the idea of using metabolic probes by stating that they are easier to use because the concentrations are orders of magnitude higher, providing a reason to consider them."
        }
    },
    {
        "utterance": "Brad Smith, Notre Dame: The problem with metabolic probes is that the cells have to be metabolically active. So you know, in the bacteria, once you get biofilms and the things calm down, then then really they're not taking up much stuff and so they get harder metabolic probes struggle that way then. ",
        "annotations": [
            {
                "provide supporting evidence": "Brad Smith provides evidence to support the challenges of using metabolic probes, stating that cells need to be metabolically active for them to work, which is a problem when cells calm down."
            }
        ]
    },
    {
        "utterance": "Brian Pogue - Dartmouth: I think there's some cool research too. ",
        "annotations": {
            "express enthusiasm": "Brian expresses enthusiasm by saying there is some cool research, which is a general encouragement."
        }
    },
    {
        "utterance": "Mark Selimyer (UPenn): Brian from, you know, Anna Woo's group out at City of Hope and and you probably know her and looking at immune cells, cell surface markers, right? So how do you track CD8 T cells and them wandering around and getting into tumors or not with immunotherapies and things like that. ",
        "annotations": {
            "expand on existing idea": "Mark is expanding on the discussion of imaging and probes by mentioning Anna Woo's group and their work on tracking immune cells with cell surface markers, building on the previous discussion of metabolic probes and imaging techniques.",
            "provide supporting evidence": "Mark mentions Anna Woo's group at City of Hope as an example of research focused on tracking immune cells using cell surface markers, providing a real-world example to support the discussion on imaging techniques."
        }
    },
    {
        "utterance": "Brian Pogue - Dartmouth: Yeah, the challenge I always talk about is is immunology exists at the nanomolar level really and and and metabolism exists at the micromolar level and it's it's a whole lot easier to image micromolars than it is to image nanomolars. ",
        "annotations": {
            "explain or define term or concept": "Brian explains the difference between immunology and metabolism in terms of concentration levels (nanomolar vs micromolar) to highlight the challenges in imaging them, building on the discussion about immune and metabolic probes.",
            "provide supporting evidence": "Brian provides the concentration levels of immunology and metabolism to support his claim that it is easier to image micromolars than nanomolars, which is relevant to the discussion about imaging probes."
        }
    },
    {
        "utterance": "Mark Selimyer (UPenn): I think they're going after, you know, cell specific markers that are on the surface using things like immuno pet probes where you've got an antibody that's specific for that. ",
        "annotations": {
            "expand on existing idea": "Mark is expanding on the discussion of imaging techniques, specifically mentioning the use of immuno-PET probes to target cell-specific markers, which builds upon the previous discussion of metabolic and immune probes."
        }
    }
]